The mission of the Transgenic Animal Shared Facility (TASF) is to provide comprehensive support in the development of novel transgenic models for the study of human cancer diseases. The core accomplishes this mission by providing the technologies and capabilities to assure the integrity of the model, from design of the transgene through production of the model organism, including all husbandry methods to assure health and long-term preservation. The TASF is a vital component of the UAB Comprehensive Cancer Center, and its research enterprise. Genetically modified murine models continue to be the most tractable system to examine the role of an identified genetic variant associated with human disease, as well as creating much needed translational models for developing novel therapeutics. This shared facility provides unique services for model development and has a long track record of outstanding service. Twenty-two funded CCC investigators used the service to generate models, and have used them to conduct pre-clinical trials for treatments of cancers such as neurofibromatosis, to understand key mechanisms in breast cancer pathogenesis, and to understand the roles of mitochondrial inheritance in cancer. Although there are external commercial or academic alternatives for generating genetic models, they are often prohibitively costly, and there are none that supply the complete set of services provided by this facility in a convenient and timely manner.
Appropriate genetic models are critical for understanding the roles of specific genes in the genesis and progression of cancer. They are also necessary for creating translational models that allow for the development of novel therapeutics. Our ability to apply genetic technologies supports the work of CCC investigators in their efforts to understand and develop treatments for the myriad forms of cancer.
|Subramaniam, Akila; Blanchard, Christina T; Erickson, Britt K et al. (2018) Feasibility of Complete Salpingectomy Compared With Standard Postpartum Tubal Ligation at Cesarean Delivery: A Randomized Controlled Trial. Obstet Gynecol 132:20-27|
|Kasten, Benjamin B; Oliver, Patsy G; Kim, Harrison et al. (2018) 212Pb-Labeled Antibody 225.28 Targeted to Chondroitin Sulfate Proteoglycan 4 for Triple-Negative Breast Cancer Therapy in Mouse Models. Int J Mol Sci 19:|
|Stoll, Matthew L; Weiss, Pamela F; Weiss, Jennifer E et al. (2018) Age and fecal microbial strain-specific differences in patients with spondyloarthritis. Arthritis Res Ther 20:14|
|Garner, Evan F; Williams, Adele P; Stafman, Laura L et al. (2018) FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts. Sci Rep 8:6913|
|Locke, Landon W; Kothandaraman, Shankaran; Tweedle, Michael et al. (2018) Use of a leukocyte-targeted peptide probe as a potential tracer for imaging the tuberculosis granuloma. Tuberculosis (Edinb) 108:201-210|
|Fancy, Romone M; Kim, Harrison; Napier, Tiara et al. (2018) Calmodulin antagonist enhances DR5-mediated apoptotic signaling in TRA-8 resistant triple negative breast cancer cells. J Cell Biochem 119:6216-6230|
|Barrington, David A; Champion, Macie L; Boitano, Teresa K L et al. (2018) Characteristics of African American women at high-risk for ovarian cancer in the southeast: Results from a Gynecologic Cancer Risk Assessment Clinic. Gynecol Oncol 149:337-340|
|Banerjee, N Sanjib; Wang, Hsu-Kun; Beadle, James R et al. (2018) Evaluation of ODE-Bn-PMEG, an acyclic nucleoside phosphonate prodrug, as an antiviral against productive HPV infection in 3D organotypic epithelial cultures. Antiviral Res 150:164-173|
|Keene, Kimberly S; King, Tari; Hwang, E Shelley et al. (2018) Molecular determinants of post-mastectomy breast cancer recurrence. NPJ Breast Cancer 4:34|
|Kleinpeter, Alex B; Jureka, Alexander S; Falahat, Sally M et al. (2018) Structural analyses reveal the mechanism of inhibition of influenza virus NS1 by two antiviral compounds. J Biol Chem 293:14659-14668|
Showing the most recent 10 out of 747 publications